Navigation Links
Accuray Reports Record Revenue in First Quarter of Fiscal 2008

Record Quarterly Revenue of $48.6 Million

Backlog Reaches Record Level of $642 Million

SUNNYVALE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced financial results for the first quarter of fiscal 2008, ended September 29, 2007.

For the first quarter of fiscal 2008, Accuray reported record total revenue of $48.6 million, up 48 percent compared to first quarter fiscal 2007 total revenue of $32.8 million.

Net income for the period ended September 29, 2007 was $2.3 million, or $0.04 per diluted share, compared to net income of $2.0 million, or $0.04 per diluted share, which included a one-time benefit of $0.8 million ($0.02 per diluted share), during the same period in fiscal 2007. Shares used in computing fully diluted earnings per share increased to 61.2 million for the first quarter of fiscal 2008 from 49.9 million during the same period in fiscal 2007. The increase was primarily a result of Accuray's initial public offering, which took place in February 2007.

Non-cash, stock-based compensation charges for the first quarter of fiscal 2008 were $4.3 million, or $0.07 per diluted share.

The first quarter of fiscal 2008 backlog increased by $23 million from the fourth quarter fiscal 2007, to approximately $642 million, with approximately $351 million associated with CyberKnife(R) Robotic Radiosurgery System contracts and approximately $291 million associated with services and other recurring revenue. Accuray's backlog is composed of firm, signed contracts that the company believes have a substantially high probability of being recognized as revenue.

Accuray's cash balance at the end of the quarter was $192 million.

"This is the third consecutive quarter where we have achieved record levels of both revenue and backlog," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray Incorporated. "This growth is a great achievement for Accuray and we believe that it reinforces the medical community's rapid acceptance of the CyberKnife System."

As of September 29, 2007, there were 114 CyberKnife Systems installed worldwide, with 76 in the Americas, 12 in Europe, 15 in Japan and 11 in the remainder of Asia Pacific.


The following statements are forward-looking and actual results may differ materially. Please see "Safe Harbor Statement" at the end of this news release for a description of certain risk factors and reference to Accuray's quarterly and annual reports on file with the Securities and Exchange Commission.

Based on the current business outlook, Accuray is reiterating its fiscal 2008 revenue guidance of $250 million to $270 million. Accuray expects that revenue growth will be greater in the third and fourth quarters of fiscal 2008.

Earnings Call Open to Investors

Accuray will hold a conference call for financial analysts and investors today, November 7, 2007 at 2:00 p.m. PT / 5:00 p.m. ET. The conference call dial-in numbers are (888) 812-8518 (USA) or (913) 312-1446 (International), Access Code: 3456588. A live webcast of the call will also be available from the Investor Relations section on the corporate Web site at In addition, a recording of the call will be available by calling (888) 203-1112 (USA) or (719) 457-0820 (International), Access Code: 3456588, beginning at 6:00 p.m. PT / 9:00 p.m. ET, November 7, 2007 and will be available through November 21, 2007. A webcast replay will also be available from the Investor Relations section of the corporate Web site at from approximately 5:30 p.m. PT / 8:30 p.m. ET, today, through Accuray's release of fiscal second quarter 2008 results, ending on December 29, 2007.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively and with sub-millimeter accuracy. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver precise, high-dose radiation, minimizing damage to surrounding healthy tissue and eliminating the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 35,000 patients worldwide and currently more than 100 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release as to financial guidance including realization of backlog, procedure growth and market acceptance, clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: fluctuations in results of operations; reimbursement for the CyberKnife procedure in the U.S. and internationally; market acceptance of our products; governmental regulatory approvals of our products; availability of clinical data regarding our products; intellectual property protection for our products; competing products; funding requirements; the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the fiscal year ended June 30, 2007 and may be updated from time to time by our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Accuray Incorporated

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except per share data)

Three months ended

September 29, September 30,

2007 2006

Net revenue:

Products $36,984 $26,767

Shared ownership programs 2,312 2,226

Services 6,999 2,969

Other 2,351 809

Total net revenue 48,646 32,771

Cost of revenue:

Cost of products 16,440 10,716

Cost of shared ownership programs 712 606

Cost of services 4,458 1,670

Cost of other 1,125 476

Total cost of revenue 22,735 13,468

Gross profit 25,911 19,303

Operating expenses:

Selling and marketing 10,156 7,530

Research and development 7,715 6,182

General and administrative 7,901 4,619

Total operating expenses 25,772 18,331

Income from operations 139 972

Interest and other income, net 2,612 207

Income before provision for income

taxes and cumulative effect of

change in accounting principle 2,751 1,179

Provision for income taxes 486 59

Income before cumulative effect of

change in accounting principle 2,265 1,120

Cumulative effect of change in

accounting principle, net of tax of $0 - 838

Net income $2,265 $1,958

Net income per common share, basic and diluted:


Income before cumulative effect of

change in accounting principle $0.04 $0.03

Cumulative effect of change in

accounting principle - 0.02

Basic net income per share $0.04 $0.05


Income before cumulative effect of

change in accounting principle $0.04 $0.02

Cumulative effect of change in

accounting principle - 0.02

Diluted net income per share $0.04 $0.04

Weighted average common shares outstanding

used in computing net income per share:

Basic 54,025 41,445

Diluted 61,154 49,851

Cost of revenue, selling and marketing,

research and development, and general

and administrative expenses include

stock-based compensation charges as follows:

Cost of revenue $321 $217

Selling and marketing $1,107 $649

Research and development $675 $449

General and administrative $2,201 $897

Accuray Incorporated

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

September 29, June 30,

2007 2007


Current assets:

Cash and cash equivalents $192,111 $204,830

Accounts receivable, net of allowance

for doubtful accounts of $20 at

both September 29, 2007 and June 30, 2007 15,178 10,105

Inventories 17,099 16,984

Prepaid expenses and other current assets 6,470 7,937

Deferred cost of revenue -- current 24,894 30,709

Total current assets 255,752 270,565

Property and equipment, net 27,382 23,937

Goodwill 4,495 4,495

Intangible assets, net 1,120 1,184

Deferred cost of revenue -- noncurrent 30,269 30,522

Other assets 1,274 1,406

Total assets $320,292 $332,109

Liabilities and stockholders' equity

Current liabilities:

Accounts payable $11,613 $14,147

Accrued expenses 14,309 17,240

Customer advances -- current 9,355 12,634

Deferred revenue -- current 71,393 78,022

Total current liabilities 106,670 122,043

Long-term liabilities:

Customer advances -- noncurrent 14,289 8,388

Deferred revenue -- noncurrent 66,087 76,235

Total liabilities 187,046 206,666

Stockholders' equity

Preferred stock, $0.001 par value;

authorized: 5,000,000 shares at

September 29, 2007 and June 30, 2007;

no shares issued and outstanding. - -

Common stock, $0.001 par value;

authorized: 100,000,000 shares at

September 29, 2007 and June 30, 2007;

issued and outstanding: 54,563,783 and

54,525,620 shares, respectively, at

September 29, 2007 and 53,798,643

and 53,798,643 shares, respectively,

at June 30, 2007. 54 53

Additional paid-in capital 257,437 251,637

Accumulated other comprehensive

income (loss) (1) 10

Accumulated deficit (124,244) (126,257)

Total stockholders' equity 133,246 125,443

Total liabilities and stockholders'

equity $320,292 $332,109

SOURCE Accuray Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Accuray Receives FDA Clearance for New Dose Calculation Technique for Body Radiosurgery
2. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
5. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO 2007
6. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... Marne, MI (PRWEB) , ... November 26, 2015 ... ... center for substance abuse located in central Michigan, have come together on Thanksgiving ... a specially produced video, available for viewing on the Serenity Point YouTube channel, ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
(Date:11/25/2015)... 25, 2015  ARKRAY USA , ... provide evidence demonstrating the accuracy of its blood glucose ... Insulin Resistance, Diabetes and Cardiovascular Disease in ... Company,s GLUCOCARD ® 01 meter and the Assure ... The ability to accurately measure glucose levels in blood ...
Breaking Medicine Technology: